Shingles shot slashes dementia risk: a new frontier in neuroimmunology
A large-scale, real-world analysis of over 1.5 million US Medicare beneficiaries aged 65 and older has revealed that the recombinant zoster vaccine (RZV) is associated with a strikingly reduced risk of new-onset dementia, including Alzheimer’s disease and vascular dementia. Drawing on administrative claims data, researchers found that individuals who received the two-dose RZV regimen exhibited a 33% lower incidence of dementia within the first three years of follow-up compared to unvaccinated controls, after matching for age, sex, and race. The protective effect held across dementia subtypes, with a 28% reduction in Alzheimer’s disease risk and a similar magnitude for vascular dementia, and persisted beyond three years of observation. This population-level association adds to a growing body of evidence linking herpes zoster vaccination to cognitive resilience, raising provocative questions about the role of neuroimmune signaling—and perhaps even calcium-dependent pathways in glial cells—in neurodegeneration.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
